GLP-1 denied for weight loss? Here's how to fight it.

If you got a denial letter for Wegovy, Zepbound, Mounjaro, Saxenda, or Ozempic-for-weight-loss, you're not alone — these are among the most-denied prior-authorization requests in 2025-2026. The good news: most denials follow a small set of templates, and each template has a counter-argument the insurer's medical reviewers are required to consider.

This guide walks through the four denial reasons you'll see, the exact citations that work, and what you (or your prescriber) should send back.

Why insurers deny GLP-1s

GLP-1 receptor agonists are expensive ($1,000-1,400/mo retail), patient demand is enormous, and insurers have a fiduciary incentive to ration. The four denial reasons you'll see, in order of frequency:

1. Step-therapy — "must try X first" (often metformin, phentermine, or generic sibutramine equivalents)

2. BMI threshold — "you don't meet our BMI ≥30 (or ≥27 with comorbidities) requirement"

3. Documentation gap — "we didn't see evidence of prior weight-loss attempts"

4. Plan exclusion — "weight-loss medications aren't covered under this plan"

The first three are appealable with the right citations. The fourth is harder but not always fatal — see the bottom section.

The citations insurers respect

These aren't generic "current guidelines support…" — these are the specific, named, recent publications that the insurer's own clinical pharmacist will recognize:

• AHA/ACC/TOS Obesity Guidelines (2013, updated 2022) — establishes BMI ≥30 OR ≥27-with-comorbidities as the standard treatment threshold
• AACE/ACE 2016 Guidelines — advances the same threshold and explicitly endorses pharmacotherapy as first-line alongside lifestyle changes (not after lifestyle has "failed")
• STEP-1 trial (NEJM 2021) — semaglutide 2.4mg achieved 14.9% weight loss at week 68 vs 2.4% placebo
• SURMOUNT-1 trial (NEJM 2022) — tirzepatide 15mg achieved 22.5% weight loss
• Obesity Medicine Association 2023 Algorithm — endorses GLP-1s as first-line for obesity, especially with metabolic comorbidities

Cite these by name and year. "Per the AHA/ACC/TOS 2013 guidelines updated 2022, BMI ≥27 with at least one weight-related comorbidity meets the threshold for pharmacotherapy" lands very differently than "current clinical guidelines support GLP-1 use."

How to argue against step-therapy

If the denial says you have to try metformin or phentermine first, the counter-argument depends on whether you've already tried something:

• You've tried alternatives — document each attempt with dates, dose, duration, and reason for discontinuation (lack of efficacy, side effects, contraindication). One full sentence per drug. Then cite the STEP trials showing semaglutide is superior to placebo and to active comparators.
• You haven't tried alternatives, but they're contraindicated — document the contraindication. Phentermine: contraindicated with cardiovascular disease, glaucoma, or stimulant-sensitive anxiety. Metformin: contraindicated with eGFR <30 or hepatic impairment. Cite the FDA-approved labelling.
• Step-therapy timing is unreasonable — 4 weeks isn't long enough to establish failure of a weight-loss medication; 12 weeks is the field standard. Cite AACE 2016 §III.B.3.

How to argue against BMI threshold

If the denial cites BMI:

• BMI ≥27 with comorbidity — list every weight-related comorbidity present: type 2 diabetes (use the A1C value), hypertension (cite BP and meds), dyslipidemia (cite LDL/triglyceride values), obstructive sleep apnea (cite AHI from polysomnography), NAFLD (cite ALT/AST trend), PCOS, GERD, osteoarthritis. Each comorbidity that's documented in your chart counts.
• BMI exactly 27 or just under — request an upward revision based on most recent measurement, OR document waist circumference (≥35F/40M is independently a risk factor per AHA/ACC).
• BMI <27 — this is genuinely the hardest. The argument shifts to trajectory (weight gain rate, prior peak BMI, family history) and to risk-equivalent comorbidities (e.g., metabolic syndrome with three components).

How to argue against documentation gaps

If the denial says "we didn't see evidence of prior weight-loss attempts":

• Document at least 6 months of medically supervised weight management before the prescription was written. This means dated visits with weights, a documented diet/exercise plan, and (ideally) outcomes. Many practices document this poorly — your prescriber's office likely has the visits but not the structured plan. Have them write a single page summarizing the prior attempts.
• Cite AHA/ACC/TOS 2013 Section IV.A.2 — pharmacotherapy is appropriate adjunct to lifestyle, NOT a last resort after lifestyle has failed entirely.

What to do about plan exclusions

If your denial reads "this plan does not cover weight-loss medications" or similar, you're up against a contractual exclusion, which is the hardest path. Three angles:

1. Reclassify as type-2 diabetes — if you have diabetes (A1C ≥6.5) or prediabetes (A1C 5.7-6.4 OR fasting glucose 100-125), Ozempic/Mounjaro can be written for the diabetes indication, which is virtually always covered.

2. State insurance commissioner inquiry — some state regulators have pushed back on blanket weight-loss exclusions, especially when comorbidities exist. Your prescriber's appeals coordinator usually knows the receptive states.

3. ERISA §502(a) civil action — if your plan is self-funded employer plan and the exclusion is being misapplied (e.g., they're denying for diabetes too), this is a federal lawsuit angle. Speak to an ERISA attorney.

What we do

We draft your appeal letter using your specific insurer's policy language, your specific clinical scenario, and the exact guideline citations above. The letter is physician-ready — your prescriber reviews, signs, and files. Free pre-payment review — if your case isn't a candidate for a strong appeal (e.g., explicit plan exclusion with no comorbidities), we tell you so before you pay anything.

Drop your denial letter and we'll route it to the right vertical and start.

Sources

• AHA/ACC/TOS 2013 Guideline for the Management of Overweight and Obesity in Adults (updated 2022)
• AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity (2016)
• Wilding et al., NEJM 2021 (STEP 1)
• Jastreboff et al., NEJM 2022 (SURMOUNT-1)
• Obesity Medicine Association 2023 Obesity Algorithm
• KFF, "Claims Denials and Appeals in ACA Marketplace Plans" (2024)